Showing 1,241 - 1,260 results of 1,405 for search '"immunotherapy"', query time: 0.06s Refine Results
  1. 1241

    Identification of signaling networks associated with lactate modulation of macrophages and dendritic cells by Rapeepat Sangsuwan, Bhasirie Thuamsang, Noah Pacifici, Phum Tachachartvanich, Devan Murphy, Abhineet Ram, John Albeck, Jamal S. Lewis

    Published 2025-02-01
    “…The advancement in the understanding of cancer immune evasion has manifested the development of cancer immunotherapeutic approaches such as checkpoint inhibitors and interleukin agonists. Although cancer immunotherapy breakthroughs have demonstrated improved potency for cancer treatment, only a fraction of patients effectively respond to these treatments. …”
    Get full text
    Article
  2. 1242

    Single-cell sequencing elucidates the mechanism of NUSAP1 in glioma and its diagnostic and prognostic significance by Meng-Yu Zhao, Zhao-Lei Shen, Hongzhen Dai, Wan-Yan Xu, Li-Na Wang, Yu- Gu, Jie-Hui Zhao, Tian-Hang Yu, Cun-Zhi Wang, Jia-feng Xu, Guan-Jun Chen, Dong-Hui Chen, Wen-Ming Hong, Wen-Ming Hong, Fang Zhang

    Published 2025-02-01
    “…In-depth exploration of NUSAP1’s mechanisms in glioblastoma could enhance our understanding of its response to immunotherapy, suggesting that targeting NUSAP1 may offer therapeutic benefits for glioma patients.…”
    Get full text
    Article
  3. 1243

    Advances in Cell and Immune Therapies for Melanoma by Tanase Timis, Sanda Buruiana, Delia Dima, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Adrian-Bogdan Tigu, Ciprian Tomuleasa

    Published 2025-01-01
    “…Melanoma is regarded as one of the most inflamed cancers due to its high immune cell presence and strong response to immunotherapy, fueling the need for development of immune-driven innovative treatments. …”
    Get full text
    Article
  4. 1244
  5. 1245

    HLA-DMB correlates with antitumor immunity and an improved prognosis in endometrial carcinoma tumors by Xiaoyu Xi, Xiaona Zhang, Jianxin Tang, Xiumei Fan, Jiexian Du

    Published 2025-01-01
    “…In our drug analysis, we identified several chemical agents associated with HLA-DMB, including cisplatin, dexamethasone, and ethinylestradiol.DiscussionThis study elucidates the function and underlying mechanisms of HLA-DMB in UCEC, providing a potential biomarker and target for immunotherapy in this disease.…”
    Get full text
    Article
  6. 1246

    Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study by Haiqing Zhao, Wei Zhang, Yuting Lu, Yin Dong, Zhihao He, Hongchao Zhen, Qin Li

    Published 2024-09-01
    “…Conclusion Inosine had a tendency to enhance the efficacy of immune‐checkpoint inhibitors and reduced immunotherapy‐related adverse reactions.…”
    Get full text
    Article
  7. 1247
  8. 1248
  9. 1249

    Isotype diversity of antibodies specific for component allergens in the context of allergic diseases: eosinophilic esophagitis (EoE), asthma, and the alpha-gal syndrome (AGS) by Thomas A. E. Platts-Mills, Matthew H. MacCallum, Jeffrey M. Wilson, Lisa J. Workman, Elizabeth A. Erwin

    Published 2025-02-01
    “…From the earliest days of studying the reagins in allergic sera that give rise to the Prausnitz-Kuestner reaction, there was evidence that there were other types of antibodies (Ab) specific for allergens, particularly those induced by immunotherapy. By 1980, not only was IgE recognized and could be measured, but the presence of other isotypes including IgG and IgA in patients with IgE was well established. …”
    Get full text
    Article
  10. 1250

    Fusion to Flaviviral Leader Peptide Targets HIV-1 Reverse Transcriptase for Secretion and Reduces Its Enzymatic Activity and Ability to Induce Oxidative Stress but Has No Major Eff... by Anastasia Latanova, Stefan Petkov, Yulia Kuzmenko, Athina Kilpeläinen, Alexander Ivanov, Olga Smirnova, Olga Krotova, Sergey Korolev, Jorma Hinkula, Vadim Karpov, Maria Isaguliants, Elizaveta Starodubova

    Published 2017-01-01
    “…Reverse transcriptase (RT) is a key enzyme in viral replication and susceptibility to ART and a crucial target of immunotherapy against drug-resistant HIV-1. RT induces oxidative stress which undermines the attempts to make it immunogenic. …”
    Get full text
    Article
  11. 1251
  12. 1252

    Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction by Fang Lyu, Yuxin Zhong, Qingliu He, Wen Xiao, Xiaoping Zhang

    Published 2025-01-01
    “…Drug sensitivity analyses suggested that high-risk patients had a better response to erlotinib, temsirolimus, axitinib, and sunitinib, whereas low-risk patients demonstrated greater sensitivity to pazopanib. Variability in immunotherapy responsiveness between groups was observed based on IPS and TIDE analyses. …”
    Get full text
    Article
  13. 1253

    PLGA confers upon conventional nonfluorescent molecules luminescent properties to trigger 1O2-induced pyroptosis and immune response in tumors by Lan Zou, Rujing Wang, Mengnan Zhao, Yuke Li, Chen Sun, Jinjin Xie, Yan Chen, Qian Jing, Dandan Mi, Sanjun Shi

    Published 2025-01-01
    “…Abstract Pyroptosis, a recently identified cellular demise regulated by gasdermin family proteins, is emerging as a promising avenue in cancer immunotherapy. However, the realm of light-controlled pyroptosis in cancer cells remains largely unexplored. …”
    Get full text
    Article
  14. 1254

    Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Revi... by Yuhan Wei, Yongfu Li, Qi Du, Xinyi Peng, Jiangtao Jin, Hong Guo, Yongyan Li, Qin Li

    Published 2020-01-01
    “…EGFR wild-type patients could benefit from immunotherapy monotherapy (HR, 0.77; P<0.001) while those of the mutant type had no survival benefit (HR, 1.11; P=0.54), and the difference was statistically significant (interaction, P=0.005). …”
    Get full text
    Article
  15. 1255

    Aberrant Expression of JAM2 Inhibits Invasion and Migration in Lung Adenocarcinoma by Jun Chen, Yuan Cui, Zhimeng Chen, Hao Ding, Chang Li, Sheng Ju, Cheng Ding, Chun Xu, Jun Zhao, Xin Tong

    Published 2025-01-01
    “…Additionally, JAM2 played a crucial role in LUAD inflammatory infiltration, and higher JAM2 expression predicted a better immunotherapy response. Conclusion JAM2 may serve as a promising molecular target for early diagnosis and targeted therapy of LUAD. …”
    Get full text
    Article
  16. 1256

    Multidimension Analysis of the Prognostic Value, Immune Regulatory Function, and ceRNA Network of LY6E in Individuals with Colorectal Cancer by Ting Li, Weidong Liu, Chun Wang, Man Wang, Wenjia Hui, Jiajie Lu, Feng Gao

    Published 2022-01-01
    “…Moreover, the high levels of LY6E expression were correlated with copy number gain, microsatellite instability high, and immunotherapy response. The results of CIBERSORT analysis demonstrated that the LY6E expression levels were correlated with the infiltration of multiple immune cells, especially T cells. …”
    Get full text
    Article
  17. 1257

    Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane by Marijke Linschoten, Jesse Geels, Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E. D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen Crommelin, Marleen Breems-de Ridder, Astrid Schut, Folkert W. Asselbergs, Anna van Rhenen, on behalf of the HOVON 170 DLBCL – ANTICIPATE consortium

    Published 2025-01-01
    “…This trial aims to establish the efficacy and safety of dexrazoxane for the primary prevention of AICD in patients diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) treated with six cycles R-CHOP21 chemo-immunotherapy. Methods This is a multicenter, parallel-group, open-label, phase III trial, randomizing 324 patients between either no cardioprotective treatment or dexrazoxane from the first R-CHOP cycle. …”
    Get full text
    Article
  18. 1258

    Changes in and Potential Mechanisms of Circulating IgA+CD27-Class-Switched Memory B Cells in Patients With Allergic Rhinitis by Zheng H, Xu S, Yang R, Jiao WE, Qiao YL, Liu JY, Fan HM, Zhou YT, Ni HF, Chen J, Deng YQ, Chen SM

    Published 2025-01-01
    “…Han Zheng,1,&ast; Shan Xu,1,&ast; Rui Yang,1,&ast; Wo-Er Jiao,1 Yue-Long Qiao,1,2 Jia-Yu Liu,1 Hui-Ming Fan,1 Yan-Ting Zhou,1 Hai-Feng Ni,3 Jin Chen,1 Yu-Qin Deng,1 Shi-Ming Chen1 1Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China; 2Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland; 3Department of Otolaryngology-Head and Neck Surgery, Zhejiang Hospital, Hangzhou, Zhejiang, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yu-Qin Deng; Shi-Ming Chen, Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China, Email bamboo0723@126.com; shimingchen0468@163.comBackground: The role of memory B cells and their subgroups in allergic rhinitis (AR) and allergen immunotherapy (AIT) remains unclear. This study aimed to investigate the characteristics of memory B cells in the circulation of patients with AR and those undergoing AIT, as well as their clinical significance.Methods: This study involved a cohort comprising 32 healthy control subjects, 39 individuals diagnosed with AR, and 31 AR patients who had received AIT for over one year. …”
    Get full text
    Article
  19. 1259

    Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States by Andrea Bilger, Eion Plenn, Frances K. Barg, Katharine A. Rendle, William B. Carter, Andrea Lamour-Harrington, Nora Jones, Beth Peterson, John A. Sauceda, Pablo Tebas, Karam Mounzer, David Metzger, Luis J. Montaner, Karine Dubé

    Published 2023-12-01
    “…Methods From April to November 2022, we conducted post-ATI in-depth interviews with BEAT2 clinical trial (NCT03588715) participants who stopped ART while receiving an immunotherapy regimen. We used conventional content analysis to code the data. …”
    Get full text
    Article
  20. 1260

    Identification of SETD4 as an Onco‐Immunological Biomarker Encompassing the Tumor Microenvironment, Prognoses, and Therapeutic Responses in Various Human Cancers by Yuyun Zhong, Ruiqi Wang, Zijie Huang, Zhaoting Hu, Bin Peng, Bin Chen, Liyue Sun

    Published 2025-01-01
    “…Furthermore, we investigated its association with cancer‐related pathways, the immune microenvironment, immunotherapy markers, and drug resistance signatures of chemotherapy. …”
    Get full text
    Article